Alkem MedTech Pvt Ltd, a wholly-owned subsidiary of Alkem Laboratories, has announced the execution of a binding offer to acquire a majority stake of up to 55% in Occlutech Holding AG, a global leader in minimally invasive cardiac implants based in Switzerland. The transaction value is set at EUR 99.4 million (Approx. INR 1,074 crore). This move marks Alkem MedTech’s strategic entry into the advanced cardiovascular devices segment, leveraging Occlutech’s strong presence in Europe and the US.
Strategic Acquisition in Medical Devices Sector
Alkem MedTech Pvt Ltd, the medical devices subsidiary of Alkem Laboratories Ltd, today announced its intent to acquire a majority stake of up to 55% in Occlutech Holding AG. The acquisition is valued at EUR 99.4 million (approximately INR 1,074 crore), subject to requisite statutory approvals. This transaction is positioned as a major step for Alkem MedTech in establishing a global footprint, particularly within the advanced cardiovascular devices market.
About Occlutech and Financial Context
Occlutech specializes in developing, manufacturing, and commercializing medical devices for critical areas, including congenital heart disease, stroke prevention, and heart failure. It is currently the second-largest company in Europe in the minimally invasive cardiac implants segment and the third-largest globally.
- Occlutech generated unaudited revenue of EUR 49.4 million in calendar year 2025.
- The company has achieved a Compound Annual Growth Rate (CAGR) of 15.7% over the past three years.
- Approximately 85% of its revenue is derived from key markets in Europe and the US.
The transaction is expected to conclude by June 2026, pending definitive agreements and the satisfaction of all conditions precedent, including the necessary regulatory approvals for foreign investments.
Leadership Commentary
B. N. Singh, Executive Chairman of Alkem Laboratories, stated that this acquisition reinforces Alkem’s long-term vision to become a global player in the medical devices industry.
Kaustav Banerjee, Chief Executive Officer of Alkem MedTech, highlighted that Occlutech offers established capabilities in structural heart devices and world-class R&D facilities, providing Alkem MedTech entry into high-barrier, high-value markets such as the US, Japan, and Germany.
Tor Peters, Chief Executive Officer of Occlutech, expressed confidence that Alkem’s strategic investment, combined with expected cost optimization synergies, will support the next phase of growth for Occlutech.
Alkem MedTech Overview
Alkem MedTech Pvt. Ltd. is Alkem Laboratories’ strategic entry into the medical technology sector. While currently focusing on orthopedic implants, the subsidiary is actively expanding into the cardiovascular devices segment, aiming to establish a strong global presence.
Contacts
Media Inquiries
Isha Trivedi
Email: [email protected]
Phone: +91-98925 90003
Investor Relations
Purvi Shah
Email: [email protected]
Phone: +91-84337 00890
Source: BSE
